Orphazyme Revenue and Competitors

Claim your profile




Total Funding



Estimated Revenue & Valuation

  • Orphazyme's estimated annual revenue is currently $13.2M per year.(i)
  • Orphazyme's estimated revenue per employee is $1,095,833
  • Orphazyme's total funding is $263.3M.
  • Orphazyme's current valuation is $79.8M. (January 2022)

Employee Data

  • Orphazyme has 12 Employees.(i)
  • Orphazyme grew their employee count by -77% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases, including sporadic Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), Niemann Pick Type C (NPC), and Gaucher. Anticipated completion of three potential registration studies by end 2020, with the first potential marketing authorization in 2020.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Orphazyme News

2022-03-30 - Correction: Proposal for a statutory restructuring plan

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Orphazyme is headquartered in...

2022-03-30 - Proposal for a statutory restructuring plan

Copenhagen, Denmark, March 31, 2022 – Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage...

2022-03-30 - Updated Financial Calendar for 2022

Copenhagen, Denmark, March 29, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage...

2019-08-28 - Orphazyme Partnership to Run Through Extension of Phase 3 ...

Orphazyme announced that it and Worldwide Clinical Trials will continue their collaboration through the long-term extension of a Phase 3 study ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Orphazyme Executives

Christophe BourdonChief Executive Officer
Thomas JensenChief Scientific Officer
Thomas BlaettlerChief Medical Officer
Birgitte OlanderCRO Oversight Specialist
Kim StrattonFormer CEO
Pernille CarlsenChief People Officer
Theresa StevensChief Business Officer, Corporate Secretary
Patrick LennonVP, Analytics & Operations
Kevin McCannVice President, Head of Finance
Molly PainterPresident - US
Izabella TyszlerVP, Marketing & Sales
Bent HygumVP, Global Head of Quality